NO932097L - Soft pharmaceutical capsules containing lysine clonixinate and methods for their preparation - Google Patents
Soft pharmaceutical capsules containing lysine clonixinate and methods for their preparationInfo
- Publication number
- NO932097L NO932097L NO932097A NO932097A NO932097L NO 932097 L NO932097 L NO 932097L NO 932097 A NO932097 A NO 932097A NO 932097 A NO932097 A NO 932097A NO 932097 L NO932097 L NO 932097L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- methods
- capsules containing
- containing lysine
- pharmaceutical capsules
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 2
- CVNFYQCHAWFYQI-ZSCHJXSPSA-N clonixin lysine salt Chemical compound NCCCC[C@H](N)C(O)=O.CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CVNFYQCHAWFYQI-ZSCHJXSPSA-N 0.000 title 1
- 229960003763 lysine clonixinate Drugs 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 239000007903 gelatin capsule Substances 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Myke gelatinkapsler med en fyllmasse som omfatter lysinkloniksninat som aktiv ingrediens i en hydrofil grunnmasse er beskrevet. Kapslene oppviser god lagringsstabilitet og hurtigere inntredende terapeutisk virkning ved oral tilførsel. Den hydrofile grunnmasse omfatter polyetylenglykol med en midlere inolekylvekt på 200-1000, eller en blanding av polyetylenglykol og/eller propylenkarbonat, 3-10 vektprosent glycerol og 5-15 vektprosent vann. De myke gelatinkapslene kan anvendes til behandling av smerte eller inflam- matoriske tilstander.Soft gelatin capsules having a filler comprising lysine cloninate as active ingredient in a hydrophilic matrix are described. The capsules exhibit good storage stability and faster onset of therapeutic effect by oral administration. The hydrophilic matrix comprises polyethylene glycol having an average inole molecular weight of 200-1000, or a mixture of polyethylene glycol and / or propylene carbonate, 3-10 weight percent glycerol and 5-15 weight percent water. The soft gelatin capsules can be used to treat pain or inflammatory conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4219702A DE4219702A1 (en) | 1992-06-16 | 1992-06-16 | Pharmaceutical soft capsules containing lysine clonixinate and a process for the production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO932097D0 NO932097D0 (en) | 1993-06-09 |
| NO932097L true NO932097L (en) | 1993-12-17 |
Family
ID=6461132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO932097A NO932097L (en) | 1992-06-16 | 1993-06-09 | Soft pharmaceutical capsules containing lysine clonixinate and methods for their preparation |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0574822A1 (en) |
| JP (1) | JPH0665078A (en) |
| KR (1) | KR940000108A (en) |
| CN (1) | CN1037934C (en) |
| AU (1) | AU656078B2 (en) |
| CA (1) | CA2098410A1 (en) |
| DE (1) | DE4219702A1 (en) |
| FI (1) | FI932768A (en) |
| IE (1) | IE930446A1 (en) |
| IL (1) | IL105870A (en) |
| MX (1) | MX9303582A (en) |
| NO (1) | NO932097L (en) |
| ZA (1) | ZA934222B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19849848A1 (en) * | 1998-10-29 | 2000-05-04 | Lohmann Therapie Syst Lts | Oral application, spontaneous disintegration with liquid and dosage form and process for its preparation |
| KR20030042935A (en) * | 2001-11-26 | 2003-06-02 | 알앤피코리아 주식회사 | Clonixin lysinate formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3337570A (en) * | 1965-10-23 | 1967-08-22 | Schering Corp | Substituted nicotinic acids and method for the manufacture thereof |
| US4144332A (en) * | 1976-01-05 | 1979-03-13 | The Regents Of The University Of Michigan | Process for alleviating proliferative skin diseases |
| DE4037554A1 (en) * | 1990-11-26 | 1992-05-27 | Roemmers Sa | MEDICAMENT FOR TOPICAL APPLICATION |
-
1992
- 1992-06-16 DE DE4219702A patent/DE4219702A1/en not_active Withdrawn
-
1993
- 1993-06-01 IL IL10587093A patent/IL105870A/en not_active IP Right Cessation
- 1993-06-03 AU AU40009/93A patent/AU656078B2/en not_active Ceased
- 1993-06-09 EP EP93109279A patent/EP0574822A1/en not_active Ceased
- 1993-06-09 NO NO932097A patent/NO932097L/en unknown
- 1993-06-10 KR KR1019930010541A patent/KR940000108A/en not_active Application Discontinuation
- 1993-06-11 JP JP5166129A patent/JPH0665078A/en active Pending
- 1993-06-15 IE IE044693A patent/IE930446A1/en not_active IP Right Cessation
- 1993-06-15 ZA ZA934222A patent/ZA934222B/en unknown
- 1993-06-15 MX MX9303582A patent/MX9303582A/en not_active Application Discontinuation
- 1993-06-15 CA CA002098410A patent/CA2098410A1/en not_active Abandoned
- 1993-06-16 CN CN93107267A patent/CN1037934C/en not_active Expired - Fee Related
- 1993-06-16 FI FI932768A patent/FI932768A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO932097D0 (en) | 1993-06-09 |
| KR940000108A (en) | 1994-01-03 |
| CN1037934C (en) | 1998-04-08 |
| CA2098410A1 (en) | 1993-12-17 |
| ZA934222B (en) | 1994-01-17 |
| MX9303582A (en) | 1994-04-29 |
| EP0574822A1 (en) | 1993-12-22 |
| DE4219702A1 (en) | 1993-12-23 |
| AU656078B2 (en) | 1995-01-19 |
| IL105870A0 (en) | 1993-10-20 |
| JPH0665078A (en) | 1994-03-08 |
| IL105870A (en) | 1996-12-05 |
| FI932768A (en) | 1993-12-17 |
| FI932768A0 (en) | 1993-06-16 |
| IE930446A1 (en) | 1993-12-29 |
| AU4000993A (en) | 1993-12-23 |
| CN1083702A (en) | 1994-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU681452B2 (en) | Pernasal composition and pernasal preparation containing thesame | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| IE63182B1 (en) | Instant oral-release capsule containing nifedipine | |
| KR890701109A (en) | Steroid lotion | |
| Rowe et al. | Control of pain resulting from endodontic therapy: a double-blind, placebo-controlled study | |
| AU2003218130A8 (en) | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors | |
| Gomez‐Jimenez et al. | Clinical efficacy of mild analgesics in pain following gynaecological or dental surgery: report on multicentre studies. | |
| NO932097L (en) | Soft pharmaceutical capsules containing lysine clonixinate and methods for their preparation | |
| BG60101B2 (en) | Method for preparing of 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]thionil]-1h-benzimidazo le | |
| EP0689437B1 (en) | Use of granisetron for the treatment of post-operative nausea and vomiting | |
| FI962056A (en) | New pharmaceutical composition for the manufacture of stable powder containing as active ingredient a combination of acetylsalicylic acid and methoclopramide | |
| US5741807A (en) | Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas | |
| RU97107418A (en) | CARBOHYDRATE DERIVATIVES, PHARMACEUTICAL COMPOSITION ON THEIR BASIS | |
| US4794112A (en) | Acetaminophen/hydroxyzine analgesic combinations | |
| Smolin et al. | Combined gentamicin-tobramycin-corticosteroid treatment: II. Effect on gentamicin-resistant Pseudomonas keratitis | |
| US5679713A (en) | Pharmaceutical composition containing carbachol and other cholinergic substances | |
| ATE212550T1 (en) | MEDICINAL PREPARATIONS CONTAINING TIAGABINE WITH CONTROLLED ADMINISTRATION OF ACTIVE INGREDIENTS | |
| FI932654A (en) | Hydroxamsyraderivat, som hindrar lipoxigenas | |
| Silvestri | Ichthyosiform dermatosis and deafness | |
| Roath | Management of Raynaud’s phenomenon: focus on newer treatments | |
| CN107753490A (en) | It is a kind of treat tumor radiotherapy caused by oral mucositis Percutaneously administrable preparation | |
| US20220339175A1 (en) | Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate Cancer | |
| EP0254693A1 (en) | Pharmaceutical form for enteric administration of etodolic acid or its salts, in admixture with excipients | |
| Babar et al. | Release and permeation studies of propranolol hydrochloride from hydrophilic polymeric matrices | |
| US20040097466A1 (en) | Treatment of a patient suffering from cell surface thrombosis disorders using enhanced absorption of arginine |